SCHEMBL6735900

SCHEMBL6735900

O=C(c1ccc(-c2ccccn2)nn1)N1CCN(S(=O)(=O)c2nc3ccc(Cl)cc3[nH]2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.44
METAP1 P53582 1/20 0.44
CBFB Q13951 1/20 0.44
ALDH1A1 P00352 2/20 0.44
PKM P14618 2/20 0.44
RXFP1 Q9HBX9 1/20 0.44
GAA P10253 4/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
ALOX15 P16050 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
F10 P00742 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6735897 0.93 ALDH1A1 (0.44) ALDH1A1PKMRXFP1GAASMN1; SMN2
SCHEMBL6737767 0.88 METAP2 (0.43) METAP2METAP1CBFBALDH1A1PKM
SCHEMBL6730054 0.88 METAP2 (0.44) METAP2METAP1CBFBALDH1A1PKM
SCHEMBL6730185 0.87 METAP2 (0.44) METAP2METAP1CBFBALDH1A1PKM
SCHEMBL6726324 0.87 ALDH1A1 (0.49) ALDH1A1GAASMN1; SMN2HRH4HRH3
SCHEMBL6735556 0.84 F10 (0.54) ALDH1A1PKMRXFP1GAASMN1; SMN2
SCHEMBL6731239 0.84 HRH4 (0.42) ALDH1A1PKMGAASMN1; SMN2HRH4
SCHEMBL6726545 0.84 METAP2 (0.46) METAP2METAP1CBFBALDH1A1PKM
SCHEMBL6782078 0.84 HTR2B (0.53) METAP2METAP1CBFBHRH4HRH3
SCHEMBL6730408 0.83 METAP2 (0.45) METAP2METAP1CBFBALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 METAP2 3629/4885METAP1 3239/4885CBFB 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.